Here is the design of a clinical trial:

Official Title: Randomized, Two-arm, Multicenter Study to Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery

Included conditions:
- Cerebrospinal Fluid Leak

Study Armgroups:
- {'label': 'Investigational arm', 'type': 'EXPERIMENTAL', 'description': 'Application of LIQOSEAL after closure of dura mater', 'interventionNames': ['Device: LIQOSEAL']}
- {'label': 'Control arm', 'type': 'ACTIVE_COMPARATOR', 'description': 'Application of Adherus or DurSeal after closure of dura mater', 'interventionNames': ['Device: DuraSeal, Adherus']}

Interventions:
- {'type': 'DEVICE', 'name': 'LIQOSEAL', 'description': 'Adjunctive bioresorbable patch', 'armGroupLabels': ['Investigational arm']}
- {'type': 'DEVICE', 'name': 'DuraSeal, Adherus', 'description': 'synthetic absorbable sealants', 'armGroupLabels': ['Control arm']}

Primary Outcomes:
- {'measure': 'Composite endpoint defined as successful dural repair without any of the following compared to the control group: intra-operative CSF leakage percutaneous CSF leak significant pseudomeningocele wound infection', 'timeFrame': '30 days'}

Please estimate the sample size based on the assumption: 
The power of the study is 80%, with a one-sided significance level of 5%. The expected rate of attrition is 10%.
Sample size {14}
          âSuccessâ was defined as absence of the composite endpoint. The success rate of the investigational product was set similar to that of the control devices combined. The combined success rate of the control devices was determined at 91%, based upon a comparative study of the two devices [6]. The non-inferiority margin was set at 10%, this was accordance with the design used by the control devices [6] and believed to be clinically acceptable. The power of the study is 80%, with a one-sided significance level of 5%. The expected rate of attrition is 10%. Under these assumptions, a total of 228 patients are required, 114 per arm.